Table 1. Baseline characteristics.
| Characteristic |
Fedratinib |
||
|---|---|---|---|
| 300 mg | 400 mg | 500 mg | |
| (n=10) | (n=10) | (n=11) | |
| Median age, years (range) | 57 (36–71) | 66 (47–81) | 67 (44–83) |
| Sex, n (%) | |||
| Male | 4 (40) | 6 (60) | 6 (55) |
| Female | 6 (60) | 4 (40) | 5 (45) |
| Disease subtype, n (%) | |||
| PMF | 6 (60) | 4 (40) | 8 (73) |
| PPV-MF | 3 (30) | 4 (40) | 1 (9) |
| PET-MF | 1 (10) | 2 (20) | 2 (18) |
| High-risk status, n (%) | 7 (70) | 5 (50) | 6 (55) |
| Prior hydroxyurea, n (%) | 4 (40) | 8 (80) | 8 (73) |
| JAK2V617F mutation status, n (%) | |||
| Positive | 7 (70) | 9 (90) | 10 (91) |
| Negative | 1 (10) | 1 (10) | 1 (10) |
| Unknown | 2 (20) | 0 | 0 |
| RBC transfusion dependent, n (%)a | 0 | 0 | 2 (18) |
| Median spleen volume (MRI), ml (range) | 2603 | 2468 | 1616 |
| (1567–7503) | (1665–8265) | (654–3770) | |
| Median MPN-SAF score at baseline (range)b | 22.5 (1–34) | 21.5 (12–39) | 18.0 (4–40) |
Abbreviations: MPN-SAF, Myeloproliferative Neoplasm Symptom Assessment Form; MRI, magnetic resonance imaging; PET-MF, post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; PPV-MF, post-polycythemia vera myelofibrosis; RBC, red blood cell.
a
Transfusion dependency is defined as receiving an average of ⩾2 units of RBC transfusion per month over 3 months.32
b
Median MPN-SAF score based on sum of six key constitutional symptoms (night sweats, pruritus, abdominal discomfort, abdominal pain, bone pain and early satiety).